Gallant announces agreement to be acquired by Dechra

Today, Dechra has signed an agreement to acquire Gallant, a U.S.-based animal health biotechnology company pioneering off-the-shelf mesenchymal stromal cell therapies for pets. This complementary transaction is aligned with Dechra’s long-term strategy to serve unmet needs in specialty care.

Gallant has become a recognized leader in regenerative medicine with capabilities that will further strengthen Dechra’s ability to advance animal health and welfare while delivering sustainable growth.

Completion of the transaction remains subject to customary closing conditions. The parties have agreed that the terms of the transaction will remain confidential.

About Gallant

Founded in 2018, Gallant is an animal health biotechnology company that delivers a pipeline of off-the-shelf stem cell therapies targeting the root causes of diseases in pets. The company operates a state-of-the-art manufacturing facility in San Diego, CA, compliant with Good Manufacturing Practices (GMP) standards. Led by pioneers in veterinary regenerative medicine with deep expertise in development, manufacturing, and commercialization, Gallant is making regenerative medicine accessible — moving beyond symptom management to restoring health at the source. Learn more at https://www.gallant.com/.

Media contact : 
Julie Lawless – LawlessComms 
[email protected]
+1.615.585.5861